Le vaccin ARN, une approche prometteuse pour la réactivation du système immunitaire dans la lutte contre le cancer

Richaud, Mathieu; Bendriss‐Vermare, Nathalie

doi:10.1051/medsci/20173310013

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunization-based therapy that utilizes antigen-presenting cells (APCs) to enhance efficacy is considered to be a promising approach for the treatment of cancer ( 6 ). Dendritic cells (DCs) serve prominent roles in various immunization therapies by activating cytotoxic T-lymphocytes (CTLs) ( 7 , 8 ). The key role of DCs in cell-mediated immunity serves as the basis for the development of effective DC vaccines for immunization therapies against tumors ( 9 , 10 ).…”

Section: Introductionmentioning

confidence: 99%

Dendritic cell vaccine with Ag85A enhances anti‑colorectal carcinoma immunity

et al. 2018

View full text Add to dashboard Cite

Dendritic cells (DCs) are able to trigger T-cell activation and thus have been considered important for vaccine production against cancers. Vaccines containing DCs have been reported to be effective for developing immunity against cancer cells. The interactions between DCs and auxiliary agents are critical in the development of second-generation vaccines. In the present study, it was evaluated whether Ag85A-mixed DCs could enhance anti-tumor immunity in laboratory mice with colorectal carcinoma. Functional and phenotypic analyses of the effects of Ag85A-mixed DCs were conducted via flow cytometry and measurement of T-cell proliferation. In addition, interferon (IFN)-γ production was assessed. The therapeutic efficacy of DC vaccination for colorectal carcinoma treatment in mice was investigated. It was identified that Ag85A-mixed DCs exhibited strong upregulation of CD80, CD86 and major histocompatibility complex class II. Cytotoxic T-lymphocytes with CT26-primed Ag85A-DCs were indicated to induce stronger responses against CT26 tumor cells and trigger IFN-γ production. Furthermore, the Ag85A-mixed DC vaccine exerted a considerable inhibitory effect on tumor progression in mice as compared with the control group. Therefore, DCs in combination with the Ag85A gene may reinforce anti-colorectal carcinoma immunity. The current study provides a novel potential strategy for cancer treatment by enhancing immunity via Ag85A-mixed DC vaccination.

show abstract